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1152Objectives: Esophageal adenocarcinoma is an aggressive malignancy generally diagnosed after metastatic
spread and currently lacks effective medical therapy. Expression of intracellular adhesion molecule-1
(ICAM-1) is an adverse prognostic indicator in various human tumor cells and contributes significantly to their
metastatic potential. Statin therapy reduces circulating ICAM-1 levels in patients with coronary heart disease
and is associated with reduction in progression from Barrett esophagus to esophageal adenocarcinoma. We hy-
pothesize that statin therapy may attenuate growth and malignant potential via ICAM-1 expression and nuclear
factor–kappa beta activation in human esophageal adenocarcinoma cells.
Methods: Verified human esophageal adenocarcinoma cells (FLO-1) were treated with simvastatin, atorvasta-
tin, or pravastatin (10-, 30-, and 50-mmol/L concentrations). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide viability, 5-bromo-20-deoxyuridine proliferation, or annexin V apoptosis assays were performed,
or cells were stimulated with tumor necrosis factor-alpha and collected for immunoblotting and flow cytometry.
Results: Simvastatin decreased cell viability and proliferation while increasing apoptosis in a dose-dependent
manner (P<.05). Simvastatin attenuated total cellular and cell-surface ICAM-1 expression as well as nuclear
factor-kappa beta activation (P<.05). Atorvastatin had mild effects and pravastatin had essentially no effect on
growth and metastatic potential of these cells.
Conclusions: We demonstrate that treatment of human esophageal adenocarcinoma cells with simvastatin at-
tenuates growth, by decreasing cell viability, decreasing cell proliferation, and increasing apoptosis, and atten-
uates metastatic potential, by decreasing expression of key metastatic markers. These findings identify
simvastatin as a potential therapeutic and chemopreventive modality to thwart the progression of esophageal
adenocarcinoma. (J Thorac Cardiovasc Surg 2011;142:1152-60)Esophageal adenocarcinoma is an aggressive malignancy
whose incidence has drastically risen in the United States
over the past 3 decades.Within certain populations, a greater
than 800% increase in incidence has been noted during
this time period.1,2 Although there have been marked
improvements in both the medical and surgical treatments
of esophageal adenocarcinoma, most patients continue to
die of metastatic disease.3 Thus, given the dismal prognosis
associated with a diagnosis of esophageal adenocarcinoma,
establishing and developing improved therapeutic and che-
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The Journal of Thoracic and Cardiovascular SurExpression of intracellular adhesion molecule-1
(ICAM-1) is an adversely associated prognostic indicator
in various human cancers, including human esophageal ad-
enocarcinoma.5,6 ICAM-1 is an adhesion molecule believed
to play a critical role in transendothelial tumor cell migra-
tion,7 and the ability of the tumor cells to spread via
ICAM-1 expression is believed to significantly contribute
to their metastatic potential. ICAM-1 expression is primar-
ily mediated by translocation of nuclear factor kappa beta
(NF-kB) into the nucleus of the cell.5,8,9 Furthermore,
extracellular factors are associated with poor prognosis
and found readily in the tumor microenvironment, such as
tumor necrosis factor-alpha (TNF-a),10 which promotes
the expression of ICAM-1 via the NF-kB pathway. This spe-
cific pathway has been associated with cancer invasion.5,9
Further supporting the importance of ICAM-1 in tumor me-
tastasis, both primary esophageal adenocarcinoma and its
metastases have been observed to express ICAM-1,
whereas normal esophageal tissue does not.6,11 Thus,
ICAM-1 expression can potentially serve as a marker of
the metastatic potential of esophageal adenocarcinoma cells
and an indicator of the patient’s prognosis.
Statins are competitive inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme A, the rate-limiting enzyme in
the pathway of cholesterol metabolism, and are classicallygery c November 2011
Abbreviations and Acronyms
ICAM-1 ¼ intracellular adhesion molecule
NF- kB ¼ nuclear factor kappa beta
TNF- a ¼ tumor necrosis factor alpha
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Sprescribed to patients as lipid-lowering agents. However,
a growing body of evidence suggests that statins also affect
numerous other intercellular processes, including pathways
responsible for producing inflammatory mediators and reg-
ulating tumor cell growth.12-16 In regard to inflammation,
statin therapy initiated for the treatment of coronary
artery disease not only decreases the risk of morbidity
associated with coronary disease but also significantly
reduces the level of circulating ICAM-1.16 In relation to
cancer cells, statin therapy has been demonstrated to inhibit
both growth and proliferation in many tumor cell types
in vitro, including esophageal adenocarcinoma.14,15,17-19
In esophageal adenocarcinoma cells, statin therapy has
been demonstrated to inhibit proliferation and induce
apoptosis via inhibition of Ras farnesylation and the
extracellular signal-regulated kinase and Akt signaling
pathways.15 Others have demonstrated simvastatin therapy
to induce apoptosis by inhibiting cyclooxygenase-2 produc-
tion in esophageal adenocarcinoma cells.19 This suggests
that statin therapy may be potentially useful in the preven-
tion or treatment of esophageal adenocarcinoma. Given the
aforementioned available data on ICAM-1 expression and
statins, we hypothesize that statin therapy may attenuate
the growth of human esophageal adenocarcinoma cells by
affecting cell viability, proliferation, and apoptosis and
also may attenuate their metastatic potential through
down-regulation of ICAM-1 expression and NF-kB activa-
tion, as determined by immunoblotting and flow cytometry,
suggesting a common pathway between the two.
MATERIALS AND METHODS
Cell Line and Drug Preparation
FLO-1 cells, a verified human esophageal adenocarcinoma cell
line,20 were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, penicillin (100 units/mL), strep-
tomycin (100 mg/mL), and fungizone (1.8 mg/mL). Cells were cultured
incubated at 37C in a humidified atmosphere of 95% air and 5% car-
bon dioxide.
Simvastatin (Sigma-Aldrich, St Louis, Mo) and atorvastatin (Sigma-Al-
drich) were dissolved in dimethyl sulfoxide. Pravastatin (Sigma-Aldrich)
was dissolved in distilled water. Before each experiment, stock solution
of each drug was diluted in serum-reduced medium (0.5% fetal bovine se-
rum), and the concentration of dimethyl sulfoxide never exceeded 0.1% in
simvastatin experiments and 0.33% in atorvastatin experiments.
Recombinant human TNF-a (Sigma-Aldrich) was reconstituted in
sterile-filtered distilled water for a final concentration of 100 ng/mL. This
was aliquoted appropriately and stored at20C until future use. At the
time of use, the stock solution was thawed and dissolved in phosphate-
buffered saline to a working concentration of 4 ng/mL.The Journal of Thoracic and CarCell Treatment
FLO-1 cells were cultured in full growth medium (10% fetal bovine
serum) at the following densities: 1 3 104 cells per well (96-well plate)
for 48 hours for cytotoxicity, viability, and proliferation assays; 5 3 105
cells per well (6-well plate) for 48 hours for apoptosis assay; 3 3 105
cells per well (6-well plate) for 48 hours for immunoblotting; and
4 3 105 cells per well (6-well plate) for 72 hours for flow cytometry.21,22
The cells were serum-reduced for the following 24 hours and then
treated with either vehicle control (dimethyl sulfoxide for simvastatin
and atorvastatin) or various concentrations (10, 30, or 50 mmol/L) of
simvastatin, atorvastatin, or pravastatin.15 All wells treated with simvas-
tatin and atorvastatin contained equivalent final dimethyl sulfoxide con-
centrations as the vehicle control. In experiments evaluating cytotoxicity,
cell viability, proliferation, and apoptosis, the assays were started
12 hours after statin treatment. In experiments evaluating ICAM-1 or
NF-kB expression, cells were stimulated 1 hour after statin treatment
with 20 ng/mL of TNF-a.21 In experiments evaluating ICAM-1 expres-
sion, cells were collected appropriately 12 hours after TNF-a stimulation
for either immunoblotting or flow cytometry. In experiments evaluating
NF-kB expression, cells were collected 10 minutes after TNF-a stimula-
tion for immunoblotting.
Cell Viability, Proliferation, and Apoptosis
Quantification After Statin Treatment
To verify that the statin therapy had no cytotoxic effects on the FLO-1
human esophageal adenocarcinoma cells, a lactate dehydrogenase cytotox-
icity assay (CaymanChemical Company, AnnArbor, Mich) was performed
on the treatment media. Lactate dehydrogenase is contained in the cellular
cytoplasm and is released into the treatment media with loss of cell mem-
brane integrity, indicating cytotoxicity resulting from stain therapy. None
of the concentrations used in this study (10, 30, or 50 mmol/L) of simvas-
tatin, atorvastatin, or pravastatin had cytotoxic effects on the cells.
After completion of the 12-hour statin treatment in 96-well plates,
cellular viability was quantified using a commercially available 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay (Roche
Diagnostics Corporation, Indianapolis, Ind) according to the manufac-
turer’s instructions.21,22
To further delineatewhether the changes in cell viability in the treatment
groups were from changes in proliferation versus apoptosis, we performed
a 5-bromo-20-deoxyuridine assay 12 hours after statin treatment according
tomanufacturer’s instructions (RocheDiagnostics Corporation). This assay
quantifies de novo DNA synthesis as a measure of proliferation.21,22
Apoptosis was quantified using a commercially available fluorescein
isothiocyanate–conjugated annexin V apoptosis detection kit (BD Biosci-
ences, San Jose, Calif). Twelve hours after statin treatment, the samples
were prepared according to the manufacturer’s instructions. Each sample
was stained with fluorescein isothiocyanate–conjugated annexin V (apo-
ptotic cells) and propidium iodide (necrotic cells). Flow cytometry
(FC500 by Beckman Coulter, Brea, Calif) was used to determine the total
percent of cells undergoing early and late apoptosis based on the total per-
cent of cells staining positive for annexin V.
Immunoblotting
Immunoblotting was used to detect ICAM-1 and activated NF-kB
(phosphorylated and total) expression as previously described.21,23
Flow Cytometry
Flow cytometry was used to detect cell-surface ICAM-1 expression as
previously described.21
Statistical Analysis
The lactate dehydrogenase cytotoxicity, cell viability (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), anddiovascular Surgery c Volume 142, Number 5 1153
FIGURE 1. Proliferation of human esophageal adenocarcinoma cells
(FLO-1) after statin therapy. Simvastatin treatment attenuated FLO-1 cell
proliferation at all concentrations (A). Atorvastatin decreased cell prolifer-
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licate wells for each experiment. The absorbance value from each well
was normalized to vehicle control, giving the vehicle control an ad-
justed unit value of 1.0. This allowed for comparison of results between
experiments and for statistical analysis. The total percentage of cells in
each sample undergoing both early and late apoptosis, as indicated by
positive annexin V staining, was used for statistical analysis.
For all immunoblotting results, a density ratio was created by dividing
the density of the primary band by the density of the glyceraldehyde-3-
phosphate dehydrogenase band. The density ratio of each sample was
then divided by the density ratio of the vehicle control on the same exper-
imental plate, giving the vehicle control an adjusted unit value of 1.0. By
normalizing to the vehicle control, results were able to be compared be-
tween experiments, allowing for statistical analysis.
For flow cytometry results, the mean intensity fluorescence of each sam-
ple was used to perform statistical analysis.
The phosphorylated and total NF-kB densities were normalized to the
glyceraldehyde-3-phosphate dehydrogenase on their respective mem-
branes, accounting for any variation in protein loading. The normalized
phosphorylated NF-kB density ratio was then divided by the normalized to-
tal NF-kB density ratio. This adjusted unit was then normalized to the ve-
hicle control to compare results between experimental groups, giving the
vehicle control an adjusted unit value of 1.0.
Data are presented as mean  standard error. Statistical analysis was
performed using analysis of variance with Fisher’s least significant differ-
ence post hoc test (StatView by SAS Institute, Inc, Cary, NC).RESULTS
Cell Viability, Proliferation, and Apoptosis of FLO-1
Human Esophageal Adenocarcinoma Cells After
Statin Therapy
Simvastatin, atorvastatin, and pravastatin did not cause
any cell necrosis at any of the concentrations used in this
study as determined by the lactate dehydrogenase cytotox-
icity assay (data not shown).
Treatment with simvastatin attenuated cell viability of
FLO-1 cells by 9.5% and 16.8% at the 30-mmol/L and
50-mmol/L concentrations, respectively, compared with
the vehicle control (P<.05, n¼ 6). Treatment with atorvas-
tatin and pravastatin did not affect the cell viability of FLO-
1 cells (n ¼ 6).
FLO-1 cell proliferation was attenuated with simvastatin
treatment by 20.4%, 37.9%, and 59.0% at the 10-, 30-, and
50-mmol/L concentrations, respectively, compared with ve-
hicle control (P<.0001) (Figure 1, A). Treatment with ator-
vastatin attenuated FLO-1 cell proliferation by 23.7% and
34.4% at the 30- and 50-mmol/L concentrations, respec-
tively (P<.01) (Figure 1, B), whereas pravastatin attenu-
ated cell proliferation by 12.3% and 13.7% at the 10- and
50-mmol/L concentrations, respectively, compared with
the vehicle control (P<.005) (Figure 1, C).ation at the 30- and 50-mmol/L concentrations (B), and pravastatin attenu-
ated proliferation of FLO-1 cells at the 10- and 50-mmol/L concentrations
(C). *P< .0001 compared with vehicle control and all concentrations;
**P<.005 compared with vehicle control; ***P<.01 compared with ve-
hicle control and 10-mmol/L concentration; n ¼ 6.
gery c November 2011
FIGURE 2. Apoptosis of human esophageal adenocarcinoma cells (FLO-
1) after statin therapy. Simvastatin treatment increased the total percentage
of FLO-1 cells undergoing early and late apoptosis at the 30- and 50-mmol/
L concentrations (A), whereas atorvastatin (B) and pravastatin (C) had no
=
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age of FLO-1 cells undergoing early and late apoptosis by
16.4% and 19.8% at the 30- and 50-mmol/L concentrations,
respectively, compared with the vehicle control (P< .05)
(Figure 2, A). Treatment with atorvastatin (Figure 2, B)
and pravastatin (Figure 2, C) did not affect the percent of
apoptotic FLO-1 cells.G
T
STotal Cellular ICAM-1 Expression After Statin
Therapy in FLO-1 Human Esophageal
Adenocarcinoma Cells
In FLO-1 human esophageal adenocarcinoma cells, the
expression of total cellular and cell-surface ICAM-1 peaks
significantly 12 hours after TNF-a administration (data not
shown). As previously shown in our laboratory, 20 ng/mL of
TNF-a stimulation significantly increased total cellular and
cell-surface ICAM-1 expression in FLO-1 cells compared
with vehicle control.21
Immunoblotting demonstrated that treatment of FLO-1
human esophageal adenocarcinoma cells with simvastatin
and atorvastatin decreased total cellular ICAM-1 expres-
sion in a dose-dependent fashion (Figure 3, A and B),
whereas pravastatin had no significant effect on total cellu-
lar ICAM-1 expression (Figure 3, C and F). The 30- and 50-
mmol/L concentrations of simvastatin produced a 31.3%
and 45.2% reduction in total cellular ICAM-1 expression,
respectively, compared with the vehicle control (P< .01)
(Figure 3, D). The 10-, 30-, and 50-mmol/L concentrations
of atorvastatin produced a 18.5%, 23.2%, and 37.7% re-
duction in total cellular ICAM-1 expression, respectively,
compared with the vehicle control (P<.05) (Figure 3, E).Cell-Surface ICAM-1 Expression After Statin
Therapy in FLO-1 Human Esophageal
Adenocarcinoma Cells
Flow cytometry demonstrated treatment of FLO-1 hu-
man esophageal adenocarcinoma cells with simvastatin at
10-, 30-, and 50-mmol/L concentrations decreased cell-
surface ICAM-1 expression 17.8%, 27.5%, and 30.6%, re-
spectively, compared with vehicle control (P < .05)
(Figure 4, A and D). Cells treated with atorvastatin had an
18.2% and 21.7% decrease in cell-surface ICAM-1 expres-
sion at the 30- and 50-mmol/L concentrations, respectively,
compared with vehicle control (P<.05) (Figure 4, B and E).
Pravastatin attenuated cell-surface ICAM-1 expression
16.2% and 13.3% at the 10- and 30-mmol/L concentrations,
respectively, compared with vehicle control (P < .05)
(Figure 4, C and F).effect on the total percentage of cells undergoing apoptosis. *P<.05 com-
pared with vehicle control and 10-mmol/L concentration; n ¼ 6.
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FIGURE 3. Total cellular ICAM-1 expression after statin therapy in human esophageal adenocarcinoma cells (FLO-1). RepresentativeWestern blots dem-
onstrate a dose-dependent attenuation of total cellular ICAM-1 expression in FLO-1 cells when treated with simvastatin (A) and atorvastatin (B), whereas
treatment with pravastatin demonstrates no significant attenuation (C and F). The 30- and 50-mmol/L concentrations of simvastatin reduced total cellular
ICAM-1 expression compared with vehicle control (D), whereas all concentrations of atorvastatin reduced total cellular ICAM-1 expression compared with
vehicle control (E). *P<.01 compared with vehicle control; **P<.01 compared with vehicle control and 10-mmol/L concentration ***P<.05 compared
with vehicle control and all concentrations; n ¼ 6. ICAM-1, Intracellular adhesion molecule-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Human Esophageal Adenocarcinoma Cells
In FLO-1 human esophageal adenocarcinoma cells, NF-
kB phosphorylation peaked 10 minutes after TNF-a admin-
istration (data not shown). When compared with the vehicle
control, immunoblotting demonstrated an attenuation of
NF-kB activation by 17.2%, 17.8%, and 30.5% after treat-
ment of FLO-1 cells with simvastatin at the 10-, 30-, and 50-
mmol/L concentrations, respectively (P<.05) (Figure 5, A
and D). Cells treated with atorvastatin and pravastatin had
no reduction in NF-kB activation compared with vehicle
control (Figure 5, B, C, E, and F).1156 The Journal of Thoracic and Cardiovascular SurDISCUSSION
The aim of this study was to determine the effect of statin
therapy on growth and metastatic potential, as determined
by the metastatic marker ICAM-1 and its mediator NF-
kB, of human esophageal adenocarcinoma cells. The results
of this study demonstrate that simvastatin treatment of
FLO-1 human esophageal adenocarcinoma cells signifi-
cantly decreased cell viability and proliferation while in-
creasing apoptosis. Additionally, simvastatin treatment
attenuated total cellular and cell-surface ICAM-1 expres-
sion and levels of activated NF-kB, suggesting a common
pathway between simvastatin’s effect on ICAM-1gery c November 2011
FIGURE 4. Cell-surface ICAM-1 expression after statin therapy in human esophageal adenocarcinoma cells (FLO-1). Representative flow cytometry his-
tograms demonstrate a reduction in mean intensity fluorescence and, thus, cell-surface ICAM-1 expression after treatment of FLO-1 cells with simvastatin
(A), atorvastatin (B), and pravastatin (C). Cell-surface ICAM-1 expression decreased with all concentrations of simvastatin (D), 30 and 50 mmol/L of ator-
vastatin (E), and 10 and 30 mmol/L of pravastatin (F). *P<.05 compared with vehicle control; **P<.05 compared with vehicle control and 10-mmol/L
concentration; n ¼ 6. ICAM-1, Intracellular adhesion molecule-1.
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FIGURE 5. NF-kB activation after statin therapy in human esophageal adenocarcinoma cells (FLO-1). Representative Western blots demonstrate a dose-
dependent attenuation in NF- kB activation in FLO-1 cells when treated with simvastatin (A), whereas treatment with atorvastatin (B and E) and pravastatin
(C and F) demonstrate no significant attenuation when compared with vehicle control. A decrease in NF-kB activation was demonstrated at all concentra-
tions of simvastatin treatment (D). *P<.05 compared with vehicle control; n ¼ 6. NF-kB, Nuclear factor kappa beta.
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milder effects than simvastatin, whereas pravastatin had es-
sentially no effect on the growth and metastatic potential of
these cells.
Statin therapy has been studied regarding its relationship
to tumorigenesis and its possible role in the treatment of
various malignancies.17 In vitro and in vivo studies alike
have demonstrated the ability of statin therapy to inhibit tu-
mor growth and induce apoptosis in a variety of malignant
cells, such as melanoma18 and colon cancer.24 Additionally,
human esophageal adenocarcinoma cells have been demon-
strated to be susceptible to treatment with statins.15,19
However, only very few reports regarding this1158 The Journal of Thoracic and Cardiovascular Surphenomenon exist. Ogunwobi and Beales15 demonstrated
statin therapy to inhibit proliferation and induce apoptosis
in OE33-verified esophageal adenocarcinoma cells via inhi-
bition of Ras farnesylation and the extracellular signal-
regulated kinase and Akt signaling pathways. Furthermore,
Konturek, Burnat, and Hahn19 demonstrated simvastatin
therapy to induce apoptosis and inhibit cyclooxygenase-2
production in OE19-verified esophageal adenocarcinoma
cells. In accordance with previously published data, our
study demonstrates the ability of statin therapy to attenuate
esophageal adenocarcinoma cell viability and proliferation
while inducing apoptosis. Interestingly, this effect varies
significantly depending on the particular statin used.gery c November 2011
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hibits ICAM-1 expression, a marker of the tumor’s meta-
static potential, as well as reducing levels of activated
NF-kB in esophageal adenocarcinoma cells, suggesting
a common pathway between the two.5,8,9 ICAM-1 is amem-
ber of a family of adhesion molecules primarily responsible
for the migration of leukocytes to the vascular endothelium
during inflammation. These leukocytes are then released
into the circulation for transport to the injured tissues. Anal-
ogous to mechanisms of inflammation, cancer cells travel to
sites beyond the primary tumor via ICAM-1. This similarity
between cellular movement in response to inflammation
and in cancer cell metastasis may provide a link between in-
flammation and tumor development, further defining a role
for anti-inflammatory therapies in the treatment of cancers
such as esophageal adenocarcinoma.25 Simvastatin’s well-
established anti-inflammatory effects coupled with its abil-
ity to attenuate ICAM-1 expression and NF-kB activation
identify simvastatin as a potential therapeutic agent to be
used synergistically with current chemotherapy in the treat-
ment of esophageal adenocarcinoma.
Although simvastatin has a significant effect on the
growth and malignant potential of esophageal adenocarci-
noma cells, atorvastatin had a minimal and variable effect
and pravastatin had virtually no effect. This inconsistency
between the effects of various statin therapies on the human
esophageal adenocarcinoma cells may be linked to the dif-
ferences in their molecular structures, directly affecting
their solubility, metabolism, and cellular localization. Spe-
cifically, the presence or absence of polar moieties on the
largely hydrophobic backbone of satins and variations in
the number of these moieties ultimately affect their lipophi-
licity. The cellular uptake of the lipophilic statins, such as
simvastatin and atorvastatin, occurs via passive diffusion,
allowing for them to be widely distributed in different tis-
sues and localize within the hydrophobic regions of the
cell. In contrast, the cellular uptake of hydrophilic statins,
such as pravastatin, occurs via carrier-mediated mecha-
nisms and localizes within polar regions of the cell.26 The
variations in cellular uptake and areas of localization be-
tween statins may directly alter their effects on the cell,
thus possibly accounting for the variation in results seen be-
tween the lipophilic simvastatin and atorvastatin as com-
pared with the hydrophilic pravastatin. Furthermore,
simvastatin is derived from a natural product whereas ator-
vastatin is a synthetic compound,27 possibly accounting for
the variability in results obtained between the 2 lipophilic
statins.
Beyond merely a mechanistic effect in vitro, a clinical ef-
fect has also been noted between statin therapy and progres-
sion of the premalignant lesion, Barrett esophagus, to the
malignant lesion, esophageal adenocarcinoma. In a nested
case–control study conducted in a cohort study of patients
diagnosed with Barrett esophagus in the Department ofThe Journal of Thoracic and CarVeterans Affairs health care system, patients on statin ther-
apy after diagnosis had a significant risk reduction for the
development of esophageal adenocarcinoma. Furthermore,
a significant trend toward a greater risk reduction with lon-
ger duration of statin therapy was noted.28 Reaching beyond
statin therapy’s ability to potentially treat the malignant le-
sion, a possible role for statin treatment in preventing the
conversion of the premalignant lesion to the malignant le-
sion exists.
Currently, patients with esophageal adenocarcinoma
have poor outcomes as a result of metastatic disease, which
lacks effective therapeutic or chemopreventive modalities.
The results of our present study demonstrate that simvasta-
tin attenuates growth of esophageal adenocarcinoma cells
as well as exhibiting the novel effect of reducing their met-
astatic potential through reduction of total cellular and se-
creted ICAM-1 expression and NF-kB activation. These
effects do not appear to be globally attributed to all statins,
which as stated previously may be due to the physical prop-
erties of the drugs themselves. Although this study demon-
strates a promising role for statin therapy in the treatment of
esophageal adenocarcinoma, examining its effects in only
one esophageal adenocarcinoma cell line limits the conclu-
sions of the study. Furthermore, the statin concentrations
used in this study are similar to various in vitro anticancer
studies, but they are difficult to accurately convert to oral
doses owing to factors such as bioavailability, bioactivity,
and patient factors. Although these concentrations show
no cytotoxicity in cells, clinical trials would have to be con-
ducted to determine patient tolerance in terms of the devel-
opment of myopathy. Despite these limitations, the findings
of this study further our interest in determining the potential
role of statin therapy in the treatment of human esophageal
adenocarcinoma.
We thank Dr David Beer (Department of Surgery, University of
Michigan, Ann Arbor, Mich) for his generous gift of the FLO-1
human esophageal adenocarcinoma cell line.
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Dr Raphael Bueno (Boston, Mass). Thank you for this elegant
presentation and elegant work. It is always nicer when the drug
that you discovered to have an effect in your cell line is approved
by the Food and Drug Administration and any physician can jus-
tify giving it. So the question for you is, what is your next step?
Are you going to add it to your postoperative regimen for patients
or are you going to do something else to look into it? If this im-
proves survival, why shouldn’t I start giving this drug to every-
body who has T3 N1 disease after resection for esophageal
cancer?
Dr Sadaria. That is an excellent question. The effects of sim-
vastatin have been investigated in various other cancers, but in
terms of esophageal adenocarcinoma, it has been researched
only in vitro. I think the next step for us is to look at it in vivo,
as you suggested, but probably in an animal model first to verify
the doses used and to ensure no adverse effects at these doses.
Depending on the results in an animal model, hoping, again, that
it will inhibit tumor metastases without significant side effects,
we will then plan to take it to the clinical level.
Dr FrankW. Sellke (Providence, RI).Did you look at other cell
surface adhesion molecules to see whether they had similar
effects?
Dr Sadaria. No, we have not evaluated other cell surface adhe-
sion molecules. Thus far in our laboratory, we have only looked at
the expression of ICAM-1. Now that we have demonstrated how
ICAM-1 expression is attenuated with simvastatin therapy, one
of the future directions we can take with this project is to look at
other cell surface adhesion molecules and observe how they may
be affected by statin therapy.
Dr Sellke. Why did you pick ICAM-1?
Dr Sadaria. ICAM-1 has actually been documented quite a bit
as a strong contributor to the tumor’s metastatic potential, more so
in other tumor cell lines than in esophageal cancer. We recently
published an article in regard to ICAM-1 and the metastatic poten-
tial of esophageal adenocarcinoma tumor cells. But again, we
based our choice of ICAM-1 on the fact that it has been widely
documented in other tumor cell lines as being an important con-
tributor in the tumor’s metastatic potential.gery c November 2011
